INCY Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 31.05% compared to Incyte Corp.'s net margin of 31.72%. Incyte Corp.'s return on equity of 31.1% beat Eli Lilly & Co.'s return on equity of 106.26%.

Incyte Corp. has a consensus price target of $102.33, signalling upside risk potential of 1.14%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that Eli Lilly & Co. has higher upside potential than Incyte Corp., analysts believe Eli Lilly & Co. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.815, which suggesting that the stock is 18.469% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Incyte Corp. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Incyte Corp. quarterly revenues are $1.4B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Incyte Corp.'s net income of $424.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Incyte Corp.'s price-to-earnings ratio is 16.97x while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 4.18x versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 31.05% compared to Incyte Corp.'s net margin of 21.32%. Incyte Corp.'s return on equity of 31.1% beat Pfizer Inc.'s return on equity of 10.84%.

Incyte Corp. has a consensus price target of $102.33, signalling upside risk potential of 1.14%. On the other hand Pfizer Inc. has an analysts' consensus of $28.78 which suggests that it could grow by 11.3%. Given that Pfizer Inc. has higher upside potential than Incyte Corp., analysts believe Pfizer Inc. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.815, which suggesting that the stock is 18.469% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.65% to investors and pays a quarterly dividend of $0.43 per share. Incyte Corp. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Incyte Corp. quarterly revenues are $1.4B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Incyte Corp.'s net income of $424.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Incyte Corp.'s price-to-earnings ratio is 16.97x while Pfizer Inc.'s PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 4.18x versus 2.35x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 31.05% compared to Incyte Corp.'s net margin of 38.89%. Incyte Corp.'s return on equity of 31.1% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Incyte Corp. has a consensus price target of $102.33, signalling upside risk potential of 1.14%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $831.38 which suggests that it could grow by 10.69%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Incyte Corp., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.815, which suggesting that the stock is 18.469% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Incyte Corp. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Incyte Corp. quarterly revenues are $1.4B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Incyte Corp.'s net income of $424.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Incyte Corp.'s price-to-earnings ratio is 16.97x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 4.18x versus 5.81x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Techne Corp. has a net margin of 31.05% compared to Incyte Corp.'s net margin of 13.32%. Incyte Corp.'s return on equity of 31.1% beat Bio-Techne Corp.'s return on equity of 3.85%.

Incyte Corp. has a consensus price target of $102.33, signalling upside risk potential of 1.14%. On the other hand Bio-Techne Corp. has an analysts' consensus of $70.00 which suggests that it could grow by 6.77%. Given that Bio-Techne Corp. has higher upside potential than Incyte Corp., analysts believe Bio-Techne Corp. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.815, which suggesting that the stock is 18.469% less volatile than S&P 500. In comparison Bio-Techne Corp. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.016%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Techne Corp. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.08 per share. Incyte Corp. pays -- of its earnings as a dividend. Bio-Techne Corp. pays out 69.67% of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Incyte Corp. quarterly revenues are $1.4B, which are larger than Bio-Techne Corp. quarterly revenues of $286.6M. Incyte Corp.'s net income of $424.2M is higher than Bio-Techne Corp.'s net income of $38.2M. Notably, Incyte Corp.'s price-to-earnings ratio is 16.97x while Bio-Techne Corp.'s PE ratio is 134.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 4.18x versus 8.50x for Bio-Techne Corp.. Usually stocks with elevated PS ratios are considered overvalued.